475585-01-4

Upstream product

• 937600-39-0 2-(4-nitro-phenyl)-oxazolo[5,4-d]pyrimidin-7-ol 
• 122-04-3 4-nitro-benzoyl chloride 

Downstream Products

• 699535-79-0 4-[7-(1-benzyl-hexahydro-pyrrolo[3,4-b]pyrrol-5-yl)-oxazolo[5,4-d]pyrimidin-2-yl]-phenylamine 
• 475585-04-7 N-(4-chlorophenyl)-2-(4-nitrophenyl)oxazolo[5,4-d]pyrimidin-7-amine 
• 475585-03-6 4-{[2-(4-nitrophenyl)oxazolo[5,4-d]pyrimidin-7-yl]amino}phenol 

Relevant academic research and scientific papers

Furo[2,3-d]pyrimidines and Oxazolo[5,4-d]pyrimidines as Inhibitors of Receptor Tyrosine Kinases (RTK)

Receptor tyrosine kinases such as VEGFR2 (vascular endothelial growth factor receptor 2, KDR) or EGFR (epidermal growth factor receptor) play crucial roles in a variety of diseases, such as cancer. Recently, some pyrrolopyrimidines were shown to be potent

Discovery and optimization of 2-aryl oxazolo-pyrimidines as adenosine kinase inhibitors using liquid phase parallel synthesis

Adenosine kinase inhibition is an attractive therapeutic approach for several conditions for example, neurodegeneration, seizures, ischemia, inflammation and pain. Several nucleosidic and non-nucleosidic inhibitors are available. Using a virtual screening approach, we have discovered that 2-aryl oxazolo-pyrimidines are adenosine kinase inhibitors. Subsequent high throughput derivatization enabled the optimization of this new inhibitor chemotype resulting in highly potent derivatives. A variety of analogues were produced by applying liquid phase parallel synthesis to vary the 7-amino residues as well as the 2-aryl moiety.